AEterna Zentaris has promoted Jurgen Engel, Ph.D. as its new president and CEO Engel is currently executive vice president and CSO of AEterna Zentaris.
Arcxis Biotechnologies has hired Christine Meda as its new president and CEO.
Vaxin has named William "Bill" Enright president and CEO.
TorreyPines Therapeutics announced that its CEO, Neil Kurtz, is leaving at the end of the month to take a new job. COO Evelyn Graham was named acting CEO.
Omrix Biopharmaceuticals named Asaf Alperovitz as CFO.
Dyax has named George Migausky as executive vice president and CFO following the retirement of Steve S. Galliker.
Actavis Group has appointed Gudbjorg Edda Eggertsdottir deputy CEO. At the same time, Valur Ragnarsson has been appointed executive vice president of third-party sales; and Doug Boothe, CEO of Actavis United States.
Biological E. Ltd. has named Rayasam (Ray) Prasad chief operating officer for global biologics.
Cortria Corporation announced the appointment of Gene Cefali, Pharm.D, Ph.D., as senior vice president of clinical pharmacology and formulation development.
Novis Pharmaceuticals named John W. Kilgour executive vice president of sales and marketing.
Nektar Therapeutics has named Randall Moreadith as its senior vice president of drug development and chief development officer.
SciClone Pharmaceuticals has named Jeffery Lange as vice president, business development.
Sucampo Pharma Europe has appointed David Dodds, MRPharmS, M.B.A., to the position of commercial director of Europe.
Ricerca Biosciences has added Desmond Cave as business development director in Europe.
Agile Therapeutics has named industry expert Al Altomari as chairman of its board of directors.
Introgen Therapeutics appointed James E. Rothman, Ph.D., to the company's board of directors.
Lux Biosciences has named Paul G. Chaney to the company's board of directors.
Richard H. Guy, Ph.D., of the University of Bath in the United Kingdom has been appointed chair of Altea Therapeutics' Scientific Advisory Board.